<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302805</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT: 2019-003723-37</org_study_id>
    <nct_id>NCT04302805</nct_id>
  </id_info>
  <brief_title>rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)</brief_title>
  <acronym>INHIBIT</acronym>
  <official_title>rATG Versus rATG Combined With IVIG Induction Immunosuppression in HLA Incompatible Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to prove similar efficacy of PE/rATG (intervention) and PE/rATG/IVIG (centre&#xD;
      standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and&#xD;
      TCMR as composite endpoint within 12 months after HLA incompatible kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have been no published clinical studies evaluating rATG/IVIG induction protocol in&#xD;
      comparison with rATG alone in defined cohort of HLA incompatible kidney transplant&#xD;
      recipients. Prescribing IVIG in management of prevention of transplant rejection is&#xD;
      considered off-label use, however IVIG remains part of induction protocols in many transplant&#xD;
      centres. IVIG therapy is demanding due to high cost and limited resources of these human&#xD;
      origin products. Trial participants will be end-stage renal disease (ESRD) patients listed&#xD;
      for deceased donor / living donor kidney transplantation with anti HLA antibody screening&#xD;
      performed within 12 months before transplantation and with last DSA 1 000 - 5 000 Mean&#xD;
      Fluorescence Intensity (MFI) and negative CDC (Complement-dependent cytotoxicity crossmatch&#xD;
      test) prior to transplantation. Participants will be randomized into one of the treatment&#xD;
      groups (PE/PP(Plasmapheresis) + rATG + IVIG, PE/PP + rATG) and as a primary outcome a&#xD;
      composite endpoint defined as occurrence of antibody- or T-cell mediated rejection within 12&#xD;
      months after transplantation will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The present study is a prospective randomized single-centre open-label two-arm Phase III.b non-inferiority clinical trial. This trial aims to prove similar efficacy of PE/rATG and PE/rATG/IVIG (centre standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and TCMR as composite endpoint within 12 months after HLA incompatible kidney transplantation.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint defined as biopsy proven antibody mediated changes (Banff 2017, Category 2) and/or TCMR (Banff 2017, Category 4) regardless the biopsy indication (for cause or protocol biopsy) in HLAi (HLA incompatible)kidney transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of biopsy-confirmed rejections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of active antibody-mediated rejection (ABMR) lesions within 12 months post-transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of active active antibody-mediated rejection (ABMR) lesions within 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to active antibody-mediated rejection (ABMR) within 12 months post-transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Time to active antibody-mediated rejection (ABMR) occurrence in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic active antibody-mediated rejection (ABMR) and C4d staining without evidence of rejection in protocol biopsies at Month 3 and Month 12</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Number of chronic active antibody-mediated rejection (ABMR) and C4d staining without evidence of rejection in protocol biopsies at Month 3 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transplant glomerulopathy (TG) in protocol biopsies at Month 3 and Month 12</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Number of biopsies with transplant glomerulopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute T-cell mediated rejection (TCMR) and chronic active TCMR in protocol biopsies at Month 3 and Month 12 post-transplantation</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Number of acute T-cell mediated rejection (TCMR) and chronic active TCMR in protocol biopsies at Month 3 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR) at Month 3, Month 6 and Month 12</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) will be assessed at all study visits by CKD-EPI formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured proteinuria and albuminuria at Month 3, Month 6 and Month 12</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Proteinuria is defined as ≥ 1 g/l and albuminuria as albumin/creatinine ratio &gt; 3 mg/mmol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor specific antibodies (DSA) at Month 3, Month 6 and Month12</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Specification of antibodies directed at HLA class I and class II will be performed by LUMINEX method (solid phase assay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De novo donor specific antibodies (DSA) at Month 3, Month 6 and Month 12</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Specification of antibodies directed at HLA class I and class II will be performed by LUMINEX method (solid phase assay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate within 12 months post-transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of deaths by any cause anytime during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival (rate of graft loss) within 12 months post transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Number graft of graft failures within 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of metabolic, malignant and cardiovascular co-morbidities</measure>
    <time_frame>12 months</time_frame>
    <description>Number of metabolic, malignant and cardiovascular co-morbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral and bacterial complications</measure>
    <time_frame>12 months</time_frame>
    <description>Number of viral and bacterial complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) replications detected by PCR (polymerase chain reaction) at Month 3, Month 6 and Month 12</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Number of patients with PCR (polymerase chain reaction) positive BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) replications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of study treatment discontinuation</measure>
    <time_frame>12 months</time_frame>
    <description>Cessation of trial medication treatment either by the clinician or by the participant himself/herself.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>PE/rATG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PE/rATG/IVIG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Privigen</intervention_name>
    <description>Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.</description>
    <arm_group_label>PE/rATG/IVIG</arm_group_label>
    <other_name>IVIG</other_name>
    <other_name>Kiovig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.</description>
    <arm_group_label>PE/rATG</arm_group_label>
    <arm_group_label>PE/rATG/IVIG</arm_group_label>
    <other_name>rATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma Exchange</intervention_name>
    <description>All patient will undergo Plasma Exchange before transplantation.</description>
    <arm_group_label>PE/rATG</arm_group_label>
    <arm_group_label>PE/rATG/IVIG</arm_group_label>
    <other_name>PE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary deceased donor or living donor kidney transplantation (first transplantation&#xD;
             or re-transplantation)&#xD;
&#xD;
          -  Recipient age ≥ 18 years and &lt; 70 years&#xD;
&#xD;
          -  Donor age &lt; 70 years&#xD;
&#xD;
          -  Written Informed Consent and Consent for Processing Personal Data&#xD;
&#xD;
          -  Last anti-HLA screening no longer than 12 months with positive results&#xD;
&#xD;
          -  MFI DSA 1 000 - 5 000 (anti-HLA A, B, DR), MFI DSA 1000-15000 for anti DQ when&#xD;
             available at randomization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined kidney transplantation with another organ&#xD;
&#xD;
          -  Immunosuppressive therapy up to 6 months before transplantation&#xD;
&#xD;
          -  AB0i (AB0 incompatible) transplantation&#xD;
&#xD;
          -  Women in childbearing potential without adequate contraception&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
          -  Leukopenia &lt; 3 000, thrombocytopenia &lt; 75 000&#xD;
&#xD;
          -  Tuberculosis history&#xD;
&#xD;
          -  Anti-HCV (Hepatitis C Virus) positivity, HBsAg (Hepatitis B Surface Antigen)&#xD;
             positivity or HBV (Hepatitis B Virus) DNA positivity&#xD;
&#xD;
          -  DSA (anti A, B, DR) measured by Luminex with MFI &gt; 5 000 known at screening prior to&#xD;
             transplant, anti DQ &gt; 15000 if known&#xD;
&#xD;
          -  FACS (flow-cytometry) T and B crossmatch positivity known at screening prior to&#xD;
             transplant&#xD;
&#xD;
          -  Positive CDC prior to transplantation&#xD;
&#xD;
          -  Planned PP/PE and RTX (Rituximab) treatment post-transplant&#xD;
&#xD;
          -  Advanced liver disease (Child-Pugh C or laboratory values of ALT or AST more than 3&#xD;
             times upper limit of normal range)&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Study medication is contraindicated according to the SmPC&#xD;
&#xD;
          -  Patient is enrolled in other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ondrej Viklicky, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ondrej Viklicky, Prof.</last_name>
    <phone>+420 261364110</phone>
    <email>ondrej.viklicky@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ondrej Viklicky, Prof.</last_name>
      <phone>261364110</phone>
      <phone_ext>+420</phone_ext>
      <email>ondrej.viklicky@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Ondřej Viklický, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Head of Department of Nephrology and Transplant Center</investigator_title>
  </responsible_party>
  <keyword>Antibody-mediated rejection</keyword>
  <keyword>Intravenous immunoglobulin</keyword>
  <keyword>Rabbit Anti-thymocyte Globulin</keyword>
  <keyword>Donor specific antibodies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

